Which statement concerning cgr ratios is least supported by data?

Which statement concerning cgr ratios is least supported by data?

• A. A high cgr ratio correlates with increased digoxin excretion
• B. The cgr operon is more active in FAA 1-3-56 than in DSM2243
• C. A low cgr ratio correlates with reduced digoxin inactivation
• D. The cgr operon abundance predicts digoxin bioavailability

Answer: (B)

The statement regarding the cgr operon being more active in FAA 1-3-56 than in DSM2243 is considered least supported by data mainly because it draws a conclusion about the relative activity levels of the cgr operon specifically in two different strains without substantial empirical evidence to back this comparison. In scientific discussions, determining the activity of operons typically requires quantitative data that includes gene expression levels, enzyme activity assays, or experimental conditions that can definitively demonstrate differences. If there is a lack of solid, comparative data regarding the operon activity in these two specific strains, it would make this statement less robust than the others. In contrast, the other statements have more consistent support from existing literature or experimental findings. For instance, the correlation of high cgr ratios with increased digoxin excretion can be linked to recognized metabolic pathway interactions, while low cgr ratios being associated with reduced digoxin inactivation likely reflects biochemical processes that have been documented. Similarly, the predictive nature of cgr operon abundance on digoxin bioavailability can be backed by studies exploring the relationship between gene expression and drug metabolism. Thus, statement B stands out as least supported due to the absence of compelling documentation comparing cgr operon activity between the two mentioned

The statement regarding the cgr operon being more active in FAA 1-3-56 than in DSM2243 is considered least supported by data mainly because it draws a conclusion about the relative activity levels of the cgr operon specifically in two different strains without substantial empirical evidence to back this comparison.

In scientific discussions, determining the activity of operons typically requires quantitative data that includes gene expression levels, enzyme activity assays, or experimental conditions that can definitively demonstrate differences. If there is a lack of solid, comparative data regarding the operon activity in these two specific strains, it would make this statement less robust than the others.

In contrast, the other statements have more consistent support from existing literature or experimental findings. For instance, the correlation of high cgr ratios with increased digoxin excretion can be linked to recognized metabolic pathway interactions, while low cgr ratios being associated with reduced digoxin inactivation likely reflects biochemical processes that have been documented. Similarly, the predictive nature of cgr operon abundance on digoxin bioavailability can be backed by studies exploring the relationship between gene expression and drug metabolism.

Thus, statement B stands out as least supported due to the absence of compelling documentation comparing cgr operon activity between the two mentioned